ethyl 3-(6-methoxypyridin-3-yl)propanoate | 72716-97-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 3-(6-methoxypyridin-3-yl)propanoate
• 英文别名: ethyl 3-(6-methoxy-pyridin-3-yl)propionate；ethyl 3-(6-methoxy-3-pyridyl)propionate
• CAS: 72716-97-3
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: QYWJJYWOBGZKHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-(6-methoxypyridin-3-yl)propanoate 在 lithium aluminium tetrahydride 作用下， 生成 3-(6-methoxypyridin-3-yl)propan-1-ol
  参考文献：
  名称：

  [EN] NOVEL PYRAZINE AMIDE COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS PYRAZINE-AMIDES

  摘要：

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R5、R6和X-具有规范中指示的含义之一，其用作药物，用于治疗呼吸道疾病或疾病和过敏性疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。

  公开号：

  WO2015018754A1
• 作为产物：
  描述：

  6-甲氧基烟腈 在 palladium on activated charcoal 、 镍 哌啶 、 吡啶 、 盐酸 、 聚合甲醛 、 氢气 、 盐酸氨基脲 、 sodium acetate 作用下， 以 乙醇 为溶剂， 反应 0.25h， 生成 ethyl 3-(6-methoxypyridin-3-yl)propanoate
  参考文献：
  名称：

  Isocytosine H2-receptor histamine antagonists. IV. The synthesis and biological activity of donetidine (SK&F 93574) and related compounds

  摘要：

  The synthesis and biological activity of some novel 2-amino-4-pyrimidone derivatives is described. Side-chains associated with H-2-antagonist activity am attached through the 2-amino group, whilst a range of 2-hydroxypyridine containing moieties are substituted at the 5-position of the pyrimidone ring. Good H-2-receptor histamine antagonist activity is observed with all the series and the majority of the compounds are selective for the H-2-receptor. High aqueous solubility and iv potency coupled with an extended duration of biological activity in animal models led to compound 16c, 2-[2-(5-dimethylaminomethyl-2-furanylmethyl-thio)ethylamino]-5-(2-hydroxypyrid-4-ylmethyl)-4-pyrimidone (donetidine, SK&F 93574) being selected for clinical investigation as a potential parenterally administered therapeutic agent.

  DOI：

  10.1016/0223-5234(93)90091-r

文献信息

• [EN] NOVEL PYRAZINE AMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS PYRAZINE-AMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015018754A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R5、R6和X-具有规范中指示的含义之一，其用作药物，用于治疗呼吸道疾病或疾病和过敏性疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• [EN] INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE αV
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089357A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（Ia）或（Ib）的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αV-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及使用这些化合物和药物组合物治疗与αV-含有整合素失调相关的疾病、紊乱或状况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• 5-(Hydroxypyridylalkyl)-4-pyrimidones
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04255428A1

  公开（公告）日：1981-03-10

  The compounds are substituted 2-amino-4-pyrimidones with a 5-(hydroxypyridylalkyl) substituent which are histamine H.sub.2 -antagonists. Two specific compounds are 2-[2-(3-bromo-2-pyridylmethylthio)ethylamino]-5-(2-hydroxy-4-pyridylmethyl )-4-pyrimidone and 2-[4-(3-methoxy-2-pyridyl)butylamino]-5-(2-hydroxy-4-pyridylmethyl)-4-pyri midone.

  这些化合物是具有5-(羟基吡啶基)取代基的2-氨基-4-嘧啶酮，是组胺H.sub.2-拮抗剂。两种特定的化合物是2-[2-(3-溴-2-吡啶甲硫基)乙基氨基]-5-(2-羟基-4-吡啶甲基)-4-嘧啶酮和2-[4-(3-甲氧基-2-吡啶基)丁基氨基]-5-(2-羟基-4-吡啶甲基)-4-嘧啶酮。
• Pyrimidine compounds
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04234588A1

  公开（公告）日：1980-11-18

  The compounds are substituted pyrimidine compounds which are histamine H.sub.2 -antagonists. A specific compound of the present invention is 2-[2-(5-dimethylaminomethyl)-2-furylmethylthio)ethylamino]-5-(3-pyridylmet hyl)-4-pyrimidone.

  这些化合物是被取代的嘧啶化合物，它们是组胺H.sub.2-拮抗剂。本发明的一种特定化合物是2-[2-(5-二甲胺甲基)-2-呋喃甲硫基)乙基氨基]-5-(3-吡啶甲基)-4-嘧啶酮。
• Intermediates in the process for making histamine antagonists
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04227000A1

  公开（公告）日：1980-10-07

  A process for making substituted 2-aminopyrimidones which are histamine H.sub.2 - antagonists which comprises reacting a 2-nitroaminopyrimidone with a heteroarylalkylamine, heteroarylalkylthioalkylamine, or heteroarylalkoxyalkylamine. One particular compound which can be made by this process is 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-[5-(1,3-benzodioxolyl) methyl]-4-pyrimidone. Also claimed are 2-nitroaminopyrimidone intermediates for use in this process. One specific intermediate is 2-nitroamino-5-[5-(1,3-benzodioxolyl)methyl]-4-pyrimidone.

  一种制备取代的2-氨基嘧啶酮的方法，该嘧啶酮是组胺H.sub.2-拮抗剂，其包括将2-硝基氨基嘧啶酮与杂环烷基胺，杂环烷基硫代烷基胺或杂环烷基氧代烷基胺反应。可以通过此方法制备的一种特定化合物是2-[2-(5-甲基-4-咪唑基甲硫基)乙基氨基]-5-[5-(1,3-苯并二氧杂环基)甲基]-4-嘧啶酮。还声明了用于此过程的2-硝基氨基嘧啶酮中间体。其中一种特定的中间体是2-硝基氨基-5-[5-(1,3-苯并二氧杂环基)甲基]-4-嘧啶酮。